Sponsorship & Exhibits

The TERMIS 2021 World Congress offers great opportunities to both commercial and non-commercial organizations, allowing them to showcase their products and services.

The TERMIS 2021 World Congress is the premier scientific event for Tissue Engineering and Regenerative Medicine in 2021. There are no continental chapter TERMIS meetings in that year.

Please apply to exhibit and sponsorship and:

  • Present your business to an international premier scientific event for Tissue Engineering en Regenerative Medicine 2021.
  • Get in front and meet new customers – explore new business opportunities
  • Promote/market your business/services

For questions with regard to the exhibition and sponsorships, please contact the Congress Secretariat:
Klinkhamer Group | conferences & events
Ms. Nadia Debie

Tel.: +31 43 362 7008
Email: info@termis2021.org

Fraunhofer Institute for Production Technology IPT

The Fraunhofer IPT combines knowledge and experience from all areas of production technology. Located in Aachen, we offer customers and partners applied research and development for networked, adaptive production. We do not only understand production in its individual steps, but also consider the entirety of the processes and the and the interconnections among various elements of the process chain. Our range of services is oriented towards the current challenges of specific industries, technologies and product areas such as tool and mould making, the optical industry, turbomachinery manufacturing, life sciences engineering and lightweight production technology.

Medical engineering, biotechnology and pharmaceuticals are characterized by a high degree of innovative strength that constantly generates new technologies and products. At the same time, industry usually places high demands on new developments in terms of safety and quality. It is therefore important for companies to make targeted use of production technologies in order to be able to deliver new products safely and cost-effectively. We are happy to support you in adapting your production strategies in order to remain competitive in the long term.

Website: https://www.ipt.fraunhofer.de


Rousselot Biomedical has drawn upon Rousselot’s 130+ years of worldwide expertise and proven track record of pharmaceutical gelatins and collagens to develop innovative ranges of purified, modified and non-modified gelatins and collagens for biomedical applications. Offering unique advantages to assure performance, quality and safety from bench to clinic, Rousselot® X-Pure® and Rousselot® Quali-Pure™ provide consistent quality and are backed by strong scientific data and on-going research.

Discover the unique advantages of X-Pure GelMA : Gelatin methacryloyl (GelMA) is probably the most popular biomaterial used in 3D bioprinting, tissue engineering and 3D cell culture applications. However, despite a steadily growing body of scientific literature and patent applications, no clinical application has made it to the patient yet.  With Rousselot X-Pure® GelMA, these applications can finally be translated to the clinic. X-Pure® GelMA is different from standard gelMAs:

  • It is a batch-to-batch consistent product
  • It is low in endotoxins and other impurities
  • It is made using a scalable process
  • It is GMP ready, meaning suitable for pre-clinical and clinical applications
  • It can be customized to meet your own needs.

Discover  X-Pure GelDAT, the world’s first purified Gelatin DesaminotyrosineX-Pure GelDAT has been developed to overcome all the challenges researchers face when using gelatin tyramine (GelTYR). GelDAT has a phenolic modification inspired by sea-mussel adhesion to wet surfaces. This phenolic modification can be crosslinked by two different cues: enzymatically (horseradish peroxidase, tyrosinase or laccase or by photo induction in the presence of a photo initiator. This versatility allows the combination with materials that polymerize under different cues to create more complex structures.

X-Pure GelDAT hydrogels are ideal for research and preclinical development in regenerative medicinedrug release and complex wound dressings due to their ability to crosslink with tissues and their purity. 

Contact us! Rousselot Biomedical is committed to support end-to-end partnerships to help “Advancing medical science”. 

Website: www.rousselot.com/biomedical

Manchester BIOGEL

Manchester BIOGEL is a leader in the design and manufacture of 3D synthetic peptide hydrogels that are redefining cell culture and 3D bioprinting for life science. Our biologically relevant PeptiGels® and PeptiInks® mimic the cell micro-environment and have tuneable properties to simulate the natural environment of all human tissues. Our PeptiGels® are specifically designed and tailored to overcome the key limitations with current biomaterials for regenerative medical applications. Our PeptiInks® are specifically designed to encapsulate and print cells with precise structural definition. Everything is 100% ethical, animal free and chemically defined, and are supplied with no batch-to-batch variability. This gives you the confidence to achieve reliable and consistent results every time, and with the adage of being clinically translatable, you have the potential to deliver life-changing therapies.

Website: www.manchesterbiogel.com 



ORCHESTRATE LIFE WITH SOUND - Next Generation Biofabrication

mimiX biotherapeutics supports the research community with ACOUSTIC BIOPRINTING, a novel R&D platform to complement and advance the existing biofabrication methodologies.

A powerful technology to push the frontiers of biofabrication.

Website: https://www.mimixbio.com


Our pursuit is progress for people everywhere. That's why we take a closer look at things, ask questions and think ahead.
We've been around for more than 350 years, yet our majority owners are still the descendants of Friedrich Jacob Merck, the man who founded our company in Darmstadt, Germany in 1668.
Since then, we have become a truly global company. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live.
From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck generated sales of € 16.2 billion in 66 countries.
We are Merck. The only exceptions are the United States and Canada. Here we operate as EMD Serono in the Biopharma business, as MilliporeSigma in the Life Science business, and as EMD Performance Materials in the materials business.

We provide infinite solutions to solve the toughest problems in life science in collaboration with the global scientific community. Our tools, services and digital platforms empower scientists and engineers at every stage, helping deliver breakthrough therapies more quickly.

Website: https://www.sigmaaldrich.com/NL/en/products/materials-science/biomedical-materials


Nordmark is a pharmaceutical company which develops and produces ingredients and drug products through all stages of the value chain. As the world's largest manufacturer of pharmaceutical collagenase, we are able to provide translational enzymes - research and GMP Grade collagenase and neutral protease products – to simplify the path from research to the clinic. Our Nordmark Biochemicals division offers products for nearly every cell isolation application. Collagenase NB 6 GMP Grade is a fast and reliable tool for stem cell isolation, proven effective by a variety of customers over many years. Additionally, we offer highly-purified, animal-free Collagenase AF-1 GMP Grade and Neutral Protease AF GMP Grade as excellent alternatives. Supporting documentation and access to Drug Master Files are available. For more information, visit:

Website: www.nordmark-biochemicals.com


REGENHU is a research driven, Swiss MedTech bioprinter pioneer committed to assisting the research and scientific communities by creating and developing state-of-the art bioprinting technologies to revolutionize medicine. Founded in 2007, the dynamic and rapidly expanding company is based in Villaz-St-Pierre, Switzerland, with offices in the United States, and distributors in Asia and Oceania.

Website: www.regenhu.com

Aspect Biosystems 

Aspect Biosystems is a Canadian biotechnology company combining the power of microfluidics and 3D bioprinting to develop bioprinted therapeutics as medicines of the future. By adopting Aspect’s microfluidic 3D bioprinting platform and collaborating within Aspect’s network, our academic collaborators are accelerating the development and commercialization of 3D bioprinted tissues. In addition, Aspect is advancing its internal regenerative medicine programs focused on bioprinted therapeutics to treat type 1 diabetes and liver disorders.

Website: www.aspectbiosystems.com


Biomomentum manufactures and commercializes the Mach-1™ mechanical tester. This all-in-one upgradable multiaxial mechanical tester is designed for compression, tension, bending, shear, friction, torsion and 3D indentation mapping of tissues and biomaterials. Unlike other micro/nanoindenters, the Mach-1 is the only tester that can automatically map the shape and mechanical properties of curved samples in 3D. This feature is particularly useful in cartilage repair pre-clinical studies where it can easily and rapidly evaluate the mechanical properties of native or regenerated articular cartilage. The Mach-1™ is now used in many university labs and is deemed an excellent educational tool for students. It has helped hundreds of scientists around the world to enhance and publish their innovative research activities. Biomomentum is also a service provider of high quality organ culture models and mechanical testing on biomaterials and tissues.

Website: www.biomomentum.com


CELLnTEC is a pioneering provider of animal and human component-free, chemically defined precision media and technologies. Across the globe, CELLnTEC empowers scientists to conduct cell culture and tissue engineering, and to create sophisticated in-vitro cell models in applications ranging from 2D/3D cell culture to organoids, lab-on-a-chip, or 3D bioprinting, across a range of tissue types, iPSC and ESC.

Our signature products are designed to successfully transverse the basic to translational research continuum and to support researchers establish clinical applications. One of the founding visions of CELLnTEC is to reduce animal testing in research. We are committed to provide non-animal, human biology-based research alternatives.   

Highlights of CELLnTEC Product Range:

  • One universal base formulation for a seamless transition across multiple applications
  • Cell expansion in serum-free, xeno-free, or fully defined environment
  • Higher Certified media: supports establishment of clinical applications
  • Precision media: accurate and highly reproducible 2D/3D in vitro modeling
  • Functional media: modeling specific cell behaviour with in vivo-like assay responsiveness and sensitivity
  • Primary cells: isolated, refined and cryopreserved in CELLnTEC media to provide users a jumpstart experience.
  • Long-Term cells: stable and dependable modeling for research in the long term
  • Supplementary reagents: cell culturing accessories

Our Prime Clients:

Basic and discovery research, pharmaceutical and regenerative medicine, wound care, cosmeceutical research, 3D bioprinting or clean meat.

Website: www.cellntec.com

Cellink Life Sciences 

Founded in 2016, CELLINK is a global life-science company that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, analysis, and liquid handling and bioprocessing, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries. CELLINK’s products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 60 countries, and have been cited in more than 200 publications. CELLINK is creating the future of medicine.

Website: www.cellink.com


XPECT-INX® is a spin-off project of Ghent University focussing on the commercialisation of materials and bio-inks for 3D bioprinting or biofabrication by utilizing decades of academic experience in the field of polymers and biomaterials. By offering a unique material portfolio with a diverse range of material properties, the applications become nearly limitless: the bio-inks can be applied for various tissue types ranging from soft tissues (e.g. adipose tissue, blood vessels, skin tissue) to hard tissues (e.g. Cartilage, bone, cornea) with applications in regenerative medicine or drug and cosmetics screening. Additionally, by offering a bio-ink portfolio suitable for multiple printing technologies, attainable resolutions range from hundreds of nanometers (multiphoton lithography), tens of micrometers (DLP printing) to hundreds of micrometers (syringe based printing).

XPECT-INX® bio-inks are based on 3 core technologies:
•Shear thinning behavior allows for easy hydrogel deposition with high shape fidelity
•CURASOL® technology enabling efficient solid-state curing of polymers which enables hydrogel processing as thermoplasts
•CURADUO® technology resulting in up to 33% faster crosslinking of gelatin-based inks

Our portfolio is subdivided in two categories:
•Extra Cellular Matrix (ECM) MIMICS can be applied both for cell-encapsulation and as a scaffolding material for cell seeding.
•SCAFFOLD INX: Specifically designed to serve as scaffolds for cell seeding. These inks are characterized by an incredible robustness.

Discover our portfolio, including the first multiphoton lithography bio-ink suitable for high resolution cell encapsulation at our booth or at www.xpect-INX.com.

Website: www.xpect-inx.com

Lifecore Biomedical

Do you need a source of Pharmaceutical Grade Sodium Hyaluronate for your TERM research and product development? For over 35 years, our hyaluronan has improved the lives of more than 100 million patients. Lifecore’s pharmaceutical grade hyaluronan is produced by bacterial fermentation in its U.S. based FDA registered/ISO 13485 certified-facility. Lifecore offers convenient quantities of sodium hyaluronate over a broad range of average molecular weights (5,000 Da. to 3M Da.) All its research lots of sodium hyaluronate are derived from pharmaceutical lots, are lot traceable, and come with a certificate of analysis.
Do you need the characteristics of hyaluronan in a longer lasting form? Lifecore’s Corgel® BioHydrogel is a biocompatible cross-linked hydrogel which is highly tunable for use in 3D constructs and cultures. Its low density tyramine based cross-linking reaction is gentle and biocompatible allowing for in situ cross-linking.
Do you have a viscous or difficult to fill TERM product that needs aseptic filling? Lifecore brings over 30 years of experience aseptically filling challenging injectable solutions in a cGMP environment.
Have you had a difficult time finding a contract manufacturer with Viscous Solutions experience? Our reliability and commitment is proven through the long-standing duration of our partnerships. Our partners are market leaders in several diverse medical segments.
How can we assist you in overcoming your challenges and realize your market opportunities? Visit us at our booth to learn more about our sodium hyaluronate and cGMP pharmaceutical compliant aseptic filling capabilities or contact Rebecca at rebecca.sebasky@lifecore.com or 952-368-6321.

Website: www.lifecore.com

Nadir Plasma and Polymers

Nadir Plasma and Polymers is an R&D company with more than 10 years experience in two innovative technologies: 

A Cold Atmospheric Plasma (CAP) proprietary technology for surface avctivation and cleaning, sterilization, and functional coating deposition.
A Clean Melt Compounding technology for the production of bioactive polymers obtained by mean of innovative smart fillers introduction.
Thanks to these two technologies we are able to provide surface modifications on every materials and bulk modification on all thermoplastic polymers of your interest.
Today, for the tissue engineering and regenerative medicine community we are providing the following innovative solutions:

At the surface, by mean of our atmospheric plasma jet device, we allow you to sterilize and improve surface wettability, adhesion between materials and molecules and to modify the surface of your interest with specific chemical functionalities able to steer cell growth. Polymeric and ceramic thin film deposition are also possible.

In the polymer bulk, by mean of our clean melt compounding technology, we are providing, custom bioactive polymer compounds like PCL/rGO, PCL/HA, PLA/HA, PEOTPBT and PolyActive ™ with active pharmaceutical ingredients (API) and other polymer compound realized on demand starting from different bioresorbable polymer and bioactive fillers . These bioactive materials will allow to realize additive manufactured parts with antimicrobial properties, cell growth differentiation properties, bone minerals properties and electroconductive properties.

Finally, both technologies can be combined in 3D printing platforms to allow our customers to print advance polymer with intrinsic regenerative properties. 3D printing platforms, then, can  be equipped with our plasma module in order to modify the surfaces of interest during the 3D printing process.

Website: www.nadir-tech.it 


„Nanoscribe develops and produces advanced high-resolution 3D printers and 2.5D Microfabrication systems as well as specially developed printing materials. The specialist for additive manufacturing on the nano-, micro- and mesoscale was founded in 2007 and is part of the BICO Group (formerly CELLINK Group) since June 2021. Today, with more than 70 employees and subsidiaries in China and the USA, Nanoscribe has become the market and technology leader. Providing complete solutions is the key to the customers’ success and the crucial driver for applications in a wide variety of sectors such as life sciences, microoptics, material engineering, microfluidics, micromechanics and MEMS. About 3,000 users and operators at top universities and innovative industrial companies worldwide benefit from the groundbreaking technology and application tailored solutions for 3D Microfabrication, highlighted in more than 1,200 peer-reviewed journal publications.

Nanoscribe systems enable additive manufacturing of high-precision biomedical components and bioinspired microenvironments at subcellular scale, suitable for cell studies and lab-on-a-chip applications such as 3D cell scaffolds to study cell growth, migration or stem cell differentiation. The 3D Microfabrication technology also advances the production of biomedical instruments needed for minimally invasive surgeries, such as implants, microneedles and microporous membranes. Various 2.5D and 3D microfluidic elements such as nozzles, filters, mixers and capillary pumps become feasible. The wide range of materials includes biocompatible, cell-binding and -repellent, hydrophobic and hydrophilic polymers, hydrogels and resins with nanoparticles. These are first and foremost the non-cytotoxic photoresin IP-Visio and the new IP-PDMS for soft, flexible and highly elastic structures in life sciences, cell and tissue engineering.“

Website: www.nanoscribe.com

Ocean TuniCell AS

Founded upon more than 20 years of research expertise in the fields of marine molecular biology, biopolymer chemistry and engineering, we supply high purity and high quality tunicate nanocellulose to the biomedical market.

We work towards a longer and healthier life for the human population. The business of Ocean TuniCell is to provide clinically relevant scaffold material that can bridge the gap between the research community and clinicians in order to facilitate the translational process in the field of regenerative medicine.

Our core activity is the production and processing of medical grade tunicate cellulose nanofibrils, TUNICELL, with fibril dimensions similar to that of native collagen in extracellular matrices, providing excellent properties for 3D reconstruction of tissues and organs. We aim to be the preferred biomaterial supplier for in vitro and in vivo biomedical applications.

Website: www.oceantunicell.com


Optics11 Life introduces innovative analysis instruments for the life sciences field. Allowing researchers to capture the complexity of life through mechanical analysis of biomaterials. Our benchtop nanoindenters are remarkably user-friendly, versatile, and robust. Our nanoindenters can do quasi-static indentations, dynamic mechanical analysis, stress relaxation, and mechanical mapping to enable full mechanical analysis.

At TERMIS 2021, we present our new Pavone instrument, designed to enable a quantitative, high-throughput analysis of the mechanical properties of any soft material, such as tissues, hydrogels, organoids, and cells. The Pavone integrates high-throughput mechanical analysis with automated microscopy and up to 96-well plate compatibility. An easy-to-use touchscreen-based interface allows you to set up large, automated experiments, reducing time spent at the instrument and maximizing throughput.

Interested in the mechanics of your samples? Come talk to us at our booth!

Website: https://www.optics11life.com/




TissueLabs is the platform for creating organs and tissues in the lab.

Our ECM-based hydrogels, MatriXpec™, are developed to offer tissue-specific microenvironments for 3D cell culture and 3D bioprinting. MatriXpec™ hydrogels allow running experiments in truly representative substrates that mimic the biological clues of the native extracellular matrix. They are available for 16 different tissues: Adipose, Bone, Brain, Cartilage, Colon, Intestine, Kidney, Liver, Lung, Muscle, Myocardium, Pancreas, Skin, Spleen, Stomach, and Vascular. Besides the conventional thermocrosslinkable MatriXpec™, we also offer it in combination with gelatin methacrylate (GelMA) - allowing photocrosslinking - and alginate/xanthan - allowing chemical crosslinking.

For those working with epithelial tissues, we offer our proprietary platform, MatriWell™, cell culture inserts were designed for fabricating 3D epithelial barriers in vitro. They contain a hydrogel with tissue-specific extracellular matrix proteins so that when cells are cultured on MatriWell™ they are exposed to an air interface on their top and a near-liquid interface on their bottom, an "air-gel interface". This setup mimics the exact microenvironment cells would find in the native tissue. 

Thinking about the researchers willing to start working with 3D bioprinting, we developed TissueStart™, the most cost-effective 3D bioprinter on the market. TissueStart™ is constructed with premium plexiglass for high resistance, long durability, and easy cleaning. It weighs only 3.6kg and does not require air compressors to operate, presenting the smallest footprint on the market. TissueStart™ is also the only 3D bioprinter offering our exclusive Mixtrusor™ system for combining multiple bioinks, allowing the fabrication of complex 3D tissues

Website: www.tissuelabs.com 

ViscoTec Pumpen- u. Dosiertechnik GmbH

More information will be availble soon. 




ZwickRoell – Your Partner in Materials Testing

You would like to characterize the mechanical behavior of biological tissues in order to understand mechanics-related pathologies such as aneurysm formation or osteoporosis and to provide the necessary building blocks for in silico testing. Then, ZwickRoell will support you!

ZwickRoell is a global leader in materials testing and your trusted partner for reliable test results. We are a medium-sized, family owned business with over 1.600 employees worldwide. Our headquarter is in Ulm – a city in the southern part of Germany We offer uniaxial testing systems for tensile, compression and flexure tests. Furthermore, we have developed biaxial and triaxial testing systems to understand the material behavior to multi-axial loads or even shear properties.

We offer standardized as well as customized testing solutions. It is also possible to integrate own e.g. 3D printed test fixtures. For tests under physiological conditions we also offer 37°C temperature chambers or temperature-controlled water baths.

Our testing software testXpert III is intuitive and workflow-based. It reduces input errors, increases efficiency and communicates with every IT system through automated importing and exporting. The unique System Configuration Builder makes it possible to define reproducible test conditions and offers maximum safety for the user and testing system.

Website: www.zwickroell.com


Simply progressive. Simply usable. Simply pure.

Puredyne represents printheads that combine the proven ViscoTec dispensing technology with single-use cartridges. Thanks to the endless piston principle, Puredyne enables volumetric dispensing - regardless of viscosities – and is particularly gentle. The new brand was created in 2021. The areas of application of the printheads include the fields of bioprinting and regenerative medicine, with plans to expand to other industries.

As the simplest, cleanest, and fastest solution for precise dispensing of viscous material in challenging bioprinting dispensing applications, the printheads are impressive - innovative and economical. The brand team maintains close contact with the market in order, on the one hand, to optimally serve the requirements of the application and, on the other hand, to recognize and react to new market trends at an early stage. Sustainable activities are closely anchored in the brand values.

Puredyne is a brand of ViscoTec Pumpen- u. Dosiertechnik GmbH. ViscoTec mainly deals with systems required for conveying, dosing, applying, filling and emptying medium to high-viscosity material. The headquarters of the technological market leader is located in Töging (Upper Bavaria, Altötting district, Germany). ViscoTec also has subsidiaries in the USA, China, Singapore, India and France and employs around 270 people worldwide.

Website: https://www.puredyne.com/en/

Science Translational Medicine / AAAS

Science Translational Medicine publishes original, peer-reviewed cutting edge research articles across all areas of biomedicine including bioengineering, devices, diagnostics, biomaterials, tissue engineering, nanotechnology, and regenerative medicine. Science Translational Medicine welcomes translational research in these fields that bridges the divide between preclinical and clinical medicine.

Website:  www.ScienceTranslationalMedicine.org

Elsevier Limited


Biomaterials and Biosystems is an interdisciplinary open access journal that publishes work at the nexus of engineering, chemistry, biology and medicine. The Journal covers the full spectrum of research, technology development and clinical translation of the biomedical engineering discipline. It is also the newest title in Elsevier’s biomaterials science portfolio, which consists Biomaterials, Materials Today Bio, Acta Biomaterialia and Materials Science and Engineering C: Materials for Biological Applications.

Biomaterials and Biosystem is organizing a special issue associated with the Tissue Engineering and Regenerative Medicine International Society (TERMIS) 6th World Congress.

This Special Issue will cover all aspects of tissue engineering and regenerative medicine, including new and established technologies that aspire to transform healthcare with their therapeutic / reparative capacity. Industry and clinical translation manuscripts are also welcome.

Other open special issues of biomaterials journal group:

Materials Today Bio:

  • Special Issue for Advanced Materials for Disease Diagnosis, guest edited by Prof. Kun Qian, Shanghai Jiao Tong University, China and Dr. Lin Huang Shanghai Jiao Tong University, China
  • CoSpecial Issue with Materials Science Materials Science and Engineering: C on Programmable Living Biomaterials, with focus on everaging synthetic biology tools to advance engineered living materials, guest edited by Chao Zhong, Shenzhen Institute of Synthetic Biology, China.

Materials Science Materials Science and Engineering: C

  • CoSpecial Issue on with Materials Today Bio on Programmable Living Biomaterials, with focus on introducing novel functionalities in biomaterials using living components, guest edited by Dr. Shrikrishnan Sankaran, INM Leibniz Institute for New Materials, Germany

Tissue Engineering


Tissue Engineering, published by Mary Ann Liebert Inc., is the preeminent, biomedical journal advancing the field with cutting-edge research and applications that repair or regenerate portions or whole tissues. The Journal is divided into three parts, providing a central forum for groundbreaking scientific research and developments of clinical applications from leading experts in the field that will enable the functional replacement of tissues. The Official Journal of the Tissue Engineering and Regenerative Medicine International Society (TERMIS). Visit our booth to learn more.


The Phil and Penny Knight Campus for Accelerating Scientific Impact 


The Phil and Penny Knight Campus for Accelerating Scientific Impact is a new campus designed to accelerate the cycle of moving discoveries to impacts for the greater good. Rooted in the University of Oregon’s 60-year history of interdisciplinary collaboration, it trains new generations of scientists, forges tighter ties with industry and entrepreneurs, and creates new opportunities for graduate and undergraduate students.


RegMed XB


RegMed XB is a virtual institute that connects Regenerative Medicine research in the Netherlands and Flanders. Crossing borders between public and private institutions, governments, health foundations, doctors, scientists and specialized companies, RegMed XB unites a common goal of the regenerative medicine community: curing chronic disease and getting the cure to the patient.

Strong partnerships backed by research funding of over 40 million euros facilitate ambitious research, currently focussing on providing a cure for patients with type 1 diabetes, kidney failure, osteoarthritis and cardiovascular disease. Future research avenues will broaden this scope to include other disease areas.

The unique blend of expertise that comes together in the RegMed XB community creates momentum to truly live up to the promise of regenerative medicine: that of restoring health rather than protracting decline, bettering the lives of millions and at the same time preventing lifelong, expensive care processes: cure instead of care.

The virtual institute has a solid program with a budget of over 10 million euros committed to the identification and support of promising research areas with the potential to developed into investable projects.  With the help of an special investment fund, the F1RST Fund, these projects can convert into an adequately funded start-up companies. A recent grant of 56 million euros from the Dutch government allows RegMed XB to grow further and to establish a pilot factory (total cost 110 million euros) for development and pilot production of Regenerative Medicine solutions. When this public-private infrastructure is in place, essential production facilities will become available to researchers and companies at acceptable costs.

The planned budget of the RegMed XB institute is more than 250 million euros for the first 10 years.